Ever Supreme Bio Technology Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 11, 2022 at 03:14 am EST
Share
Ever Supreme Bio Technology Co., Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 171.65 million compared to TWD 143.71 million a year ago. Net income was TWD 38.24 million compared to TWD 233.22 million a year ago. Basic earnings per share from continuing operations was TWD 0.5093 compared to TWD 3.1192 a year ago. Diluted earnings per share from continuing operations was TWD 0.5093 compared to TWD 3.0919 a year ago.
For the nine months, sales was TWD 447.77 million compared to TWD 283.75 million a year ago. Net income was TWD 70.54 million compared to TWD 287.46 million a year ago. Basic earnings per share from continuing operations was TWD 0.9458 compared to TWD 3.8558 a year ago. Diluted earnings per share from continuing operations was TWD 0.9367 compared to TWD 3.8285 a year ago.
Ever Supreme Bio Technology Co., Ltd. is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sales of stem cell products and immune cell products. The Company has three main products. ADCV01 is an autologous dendritic cell tumor vaccine product, which is currently in the phaseII of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product and a new drug for the treatment of myocardial infarction, which is approved by the United States Food and Drug Administration (FDA) clinical phaseI and is currently applying for the phaseI of clinical trials in Taiwan. UMSC01 is a human allogeneic umbilical cord stem cell product, which is used to treat acute ischemic stroke and is currently in the United States FDA for clinical phase I. The Company plans to develop new products and services including mesenchymal stem cells for the treatment of multiple sclerosis.
EVER SUPREME BIO TECHNOLOGY CO., LTD 
